Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study

Rivaroxaban, a direct oral anticoagulant, is effective against venous thromboembolism (VTE) recurrence without increasing the risk of major bleeding in patients with cancer-associated venous thromboembolism (CAT). However, its clot regression effects are poorly understood. This single-arm, prospecti...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-12, Vol.12 (1), p.21569-12, Article 21569
Main Authors: Takai, Shigeki, Nakanishi, Naohiko, Yokota, Isao, Imai, Kojiro, Yamada, Ayumu, Kawasaki, Takanori, Kasahara, Takeru, Okada, Takashi, Sawada, Takahisa, Matoba, Satoaki
Format: Article
Language:English
Subjects:
692/4019/592/75/593/1839
692/4019/592/75/593/567
Anticoagulants - adverse effects
Bleeding
Computed tomography
Factor Xa Inhibitors - pharmacology
Factor Xa Inhibitors - therapeutic use
Hemorrhage - chemically induced
Humanities and Social Sciences
Humans
multidisciplinary
Neoplasms - drug therapy
Prospective Studies
Rivaroxaban - pharmacology
Rivaroxaban - therapeutic use
Science
Science (multidisciplinary)
Statistical analysis
Thromboembolism
Thrombosis
Thrombosis - drug therapy
Venous Thromboembolism - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rivaroxaban, a direct oral anticoagulant, is effective against venous thromboembolism (VTE) recurrence without increasing the risk of major bleeding in patients with cancer-associated venous thromboembolism (CAT). However, its clot regression effects are poorly understood. This single-arm, prospective interventional study aimed to investigate the clot regression effects of rivaroxaban in 40 CAT patients, through a contrast-enhanced computed tomography at baseline, 3 weeks, and 3 months of rivaroxaban treatment. The primary endpoint was the clot-regression ratio calculated from the thrombus volumes at 3 weeks and 3 months. Compared with baseline, the total clot volume was significantly reduced at both 3 weeks and 3 months after initiation ( p  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-26150-w